methyl N-[(4-bromophenyl)sulfonyl]-N-methyl-L-valinate | 924369-55-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-[(4-bromophenyl)sulfonyl]-N-methyl-L-valinate
• 英文别名: methyl (2S)-2-[(4-bromophenyl)sulfonyl-methylamino]-3-methylbutanoate
• CAS: 924369-55-1
• 化学式: C₁₃H₁₈BrNO₄S
• 分子量: 364.26
• InChiKey: OWDPAIIGKOIIEV-LBPRGKRZSA-N

物化性质

• 沸点：
  425.4±55.0 °C(Predicted)
• 密度：
  1.412±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl N-[(4-bromophenyl)sulfonyl]-N-methyl-L-valinate 、 4-硝基苯基硼酸 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 碳酸氢钠 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 16.0h， 以59%的产率得到methyl N-[(4'-nitro-1,1'-biphenyl-4-yl)sulfonyl]-N-methyl-L-valinate
  参考文献：
  名称：

  WO2007/16538

  摘要：

  公开号：
• 作为产物：
  描述：

  N-methyl-L-valine methyl ester 、 4-溴苯磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以95%的产率得到methyl N-[(4-bromophenyl)sulfonyl]-N-methyl-L-valinate
  参考文献：
  名称：

  WO2007/16538

  摘要：

  公开号：

文献信息

• [EN] PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES<br/>[FR] DÉRIVÉS PYRAZOLO-TRIAZINE PHARMACEUTIQUEMENT ACTIFS
  申请人：LEAD DISCOVERY CENTER GMBH

  公开号：WO2013128029A1

  公开（公告）日：2013-09-06

  The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.

  本发明涉及吡唑咯[1,5-a][1,3,5]三唑衍生物和/或其药用可接受盐，这些衍生物的用途作为药用活性剂，特别用于预防和/或治疗传染病，包括机会性感染病、免疫性疾病、自身免疫性疾病、心血管疾病、细胞增殖性疾病、炎症、勃起功能障碍和中风，以及含有至少一种所述吡唑咯[1,5-a][1,3,5]三唑衍生物和/或其药用可接受盐的药物组合物。此外，本发明涉及所述吡唑咯[1,5-a][1,3,5]三唑衍生物作为蛋白激酶抑制剂的用途。
• Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
  申请人：Lead Discovery Center GmbH

  公开号：EP2634189A1

  公开（公告）日：2013-09-04

  The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.

  本发明涉及吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用盐，这些衍生物作为药用活性剂的应用，特别是用于预防和/或治疗传染病，包括机会性感染病、免疫性疾病、自身免疫疾病、心血管疾病、细胞增殖性疾病、炎症、勃起功能障碍和中风，以及含有至少一种所述吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用盐的药物组合物。此外，本发明涉及所述吡唑并[1,5-a][1,3,5]三嗪衍生物作为蛋白激酶抑制剂的应用。
• Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
  申请人：Lead Discovery Center GmbH

  公开号：EP2634190A1

  公开（公告）日：2013-09-04

  The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.

  本发明涉及吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用可接受盐，以及这些衍生物作为药用活性剂的用途，特别是用于预防和/或治疗传染病，包括机会性疾病、免疫疾病、自身免疫疾病、心血管疾病、细胞增殖性疾病、炎症、勃起功能障碍和中风，以及含有至少一种所述吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用可接受盐的药物组合物。此外，本发明涉及将所述吡唑并[1,5-a][1,3,5]三嗪衍生物用作蛋白激酶的抑制剂。
• [EN] METHOD AND APPARATUS FOR THE SYNTHESIS OF DIHYDROARTEMISININ AND ARTEMISININ DERIVATIVES<br/>[FR] PROCÉDÉ ET APPAREIL DE SYNTHÈSE DE DIHYDROARTÉMISININE ET DE DÉRIVÉS D'ARTÉMISININE
  申请人：MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V

  公开号：WO2015007693A1

  公开（公告）日：2015-01-22

  The present invention is directed to a method for continuous production of dihydroartemisinin and also artemisinin derivatives derived from dihydroartemisinin by using artemisinin or dihydroartemisinic acid (DHAA) as starting material as well as to a continuous flow reactor for producing dihydroartemisinin as well as the artemisinin derivatives. It was found that the reduction of artemisinin to dihydroartemisinin in a continuous process requires a special kind of reactor and a special combination of reagents comprising a hydride reducing agent, at least one activator such as an inorganic activator, at least one solid base, at least one aprotic solvent and at least one C1-C5 alcohol.

  本发明涉及一种连续生产二氢青蒿素以及由二氢青蒿素衍生的青蒿素衍生物的方法，该方法利用青蒿素或二氢青蒿酸（DHAA）作为起始物质，并且涉及一种用于生产二氢青蒿素以及青蒿素衍生物的连续流反应器。发现在连续过程中将青蒿素还原为二氢青蒿素需要一种特殊类型的反应器和一种特殊的试剂组合，包括一种氢化物还原剂，至少一种活化剂（例如无机活化剂），至少一种固体碱，至少一种无极性溶剂以及至少一种C1-C5醇。
• [EN] 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS<br/>[FR] COMPOSÉS 4-(4-PYRIMIDYL)-BENZAMIDES ET UTILISATION DE CEUX-CI COMME MODULATEURS DE L'ACTIVITÉ DE KINASES RHO (ROCK)
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2009027392A1

  公开（公告）日：2009-03-05

  The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R1 and R2 are, independently of each other, hydrogen, hydroxy, cyano, C1-C8-alkyl, C1- C8-haloalkyl, C1-C8-alkoxy or C1-C8-haloalkoxy; R3, R4, R5 and R6 are, independently of each other, hydrogen, hydroxy, halogen, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, amino, C1-C8-alkylamino or di-(C1-C8-alkyl)-amino; R7 is hydrogen, C1-C8-alkyl, C1-C8-haloalkyl, aryl or aryl-C1-C8-alkyl; R8 is a group of the formula -X-W, where X is a single bond, C1-C4-alkylene or C1-C4-alkylene-O-, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; R9 is a group of the formula -Y-Z, where Z is hydrogen, halogen, OR11, NR12R13, S(O)m-R14, phenyl which may carry 1, 2, 3 or 4 substituents R15 or a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched C1C4-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond.

  本发明涉及公式（I）的新型4-(4-吡啶基)-苯甲酰胺。化合物I具有有价值的治疗性能，并且特别适用于治疗对Rho激酶（ROCKs）调节产生反应的疾病。R1和R2分别为氢、羟基、氰基、C1-C8-烷基、C1-C8-卤代烷基、C1-C8-烷氧基或C1-C8-卤代烷氧基；R3、R4、R5和R6分别为氢、羟基、卤素、氰基、C1-C8-烷基、C1-C8-卤代烷基、C1-C8-烷氧基、C1-C8-卤代烷氧基、氨基、C1-C8-烷基氨基或二(C1-C8-烷基)-氨基；R7为氢、C1-C8-烷基、C1-C8-卤代烷基、芳基或芳基-C1-C8-烷基；R8为-X-W的基团，其中X为单键、C1-C4-烷基或C1-C4-烷基-O-，在上述最后三个基团中的烷基可以是直链或支链，可以部分或完全卤代，和/或可以被羟基取代，和/或可以被氧原子打断；W为选择自苯基和含有1、2或3个来自O、S和N的杂原子以及可选地包含1或2个羰基的5-或6-成员饱和、部分不饱和或芳香杂环的环基；R9为-Y-Z的基团，其中Z为氢、卤素、OR11、NR12R13、S(O)m-R14、可能携带1、2、3或4个取代基R15的苯基或5-或6-成员饱和、部分不饱和或芳香杂环的环基；Y为线性或支链的C1-C4-烷基，可以部分或完全卤代，和/或可以被羟基取代，和/或可以是苯环；或者，如果Z为苯基或上述定义的5-或6-成员杂环环，Y也可以是单键。